As Cybin (NEO: CYBN) (NYSE American: CYBN) continues its commitment to focus on the psychedelic therapeutic space and deliver proprietary drug-discovery platforms, the company has made key additions and changes (https://ibn.fm/0GBMQ). Most recently the company has appointed two new executives and announced internal promotions to continue strengthening its leadership team.
Cybin has named Dr. Amir Inamdar as chief medical officer for European operations and Dr. Geoff Varty as head of research and development for the company. In addition, the company announced the promotion of Lori Challenger to chief compliance, ethics and administrative officer and Robert Mino to general counsel.
A trained psychiatrist and pharmaceutical physician with more than two decades of clinical and drug development experience, Dr. Amir Inamdar has garnered invaluable experience in progressing several drugs from preclinical development to early-phase clinical trials; he also has key experience in designing and delivering proof-of-concept studies as well as leading teams through marketing authorization applications.
Inamdar’s background stretches across diverse psychiatric indications, including schizophrenia, depression, bipolar disorder, treatment-resistant mental illnesses and substance-use disorders. He has led multidisciplinary teams, providing strategic direction and clinical and scientific leadership. Inamdar has also received numerous awards for his research and development work in clinical drug development.
Inamdar has worked at GlaxoSmithKline, Takeda Pharmaceutical Company Limited and AstraZeneca. In his roles at these organizations, he developed a network of excellence in psychiatry and provided medical leadership to enable the development of candidate drugs from selection through to proof-of-concept trials across a variety of central nervous system indications. He was also key in successfully obtaining marketing authorization for an antipsychotic in Europe, progressing small molecules from candidate selection to first in-human studies, and leading clinical teams in treatment of resistant depression, narcolepsy and anxiety.
Varty too brings an impressive history of work expertise. A highly experienced neuroscientist and drug discoverer, Varty also has a track record of progressing novel molecular entities into clinical trials and to the patient. With a bachelor’s degree in pharmacology and a PhD in neuropsychopharmacology, Varty has focused his research on the development of behavioral models for psychosis and cognition, along with the preclinical testing of novel compounds. He has spent his two-decade career in the pharmaceutical industry, working in R&D and scientific leadership and managerial roles at Schering Plough, Sanofi and Merck.
While at these companies, Varty led in-vivo research in several central nervous system–related areas such as pain, anxiety, depression, schizophrenia, Parkinson’s disease and Alzheimer’s disease. He has also gained invaluable experience collaborating with cross-functional teams working together toward focused objectives. He has published more than 130 journal articles and abstracts.
Cybin is a leading biotechnology company focused on progressing psychedelic therapeutics by utilizing proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for psychiatric disorders.
For more information, visit the company’s website at www.Cybin.com.
NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.biomedwire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.
Significant strides have been made in leveraging checkpoint inhibitor therapy to combat a number of cancers over the recent…
LIXTE recently expanded its ovarian clear cell cancer trial in partnership with MD Anderson and…
California, led by Democratic governor Gavin Newsom, has decided to break with the federal positions on public health and…
Earth Science Tech is a holding company that acquires and manages businesses in several markets,…
Prof. Brown is a leading researcher in Transcranial Magnetic Stimulation (“TMS”) and currently serves as…
South Korean scientists have published the results of a study that provides vital insights indicating…